

IN THE MATTER OF
MELWOOD PHARMACY
PERMIT NO. P01278

* BEFORE THE
* MARYLAND STATE
* BOARD PHARMACY

RESPONDENT

*

* * * * *

ORDER FOR SUMMARY SUSPENSION OF PHARMACY PERMIT

Background

On April 6, 1999, the Maryland State Board of Pharmacy (the "Board") issued a notice of intent to summarily suspend the pharmacy permit held by Melwood Pharmacy, Permit No. P01278 (the "Respondent"). The Respondent was given an opportunity for a hearing to show cause as to why the Board should not issue an unexecuted order that would have suspended his pharmacy permit due to the imminent threat to the public health created by dangerous practices at the pharmacy. (See the Board' unexecuted order attached as Exhibit #1 hereto and incorporated by reference herein). A show cause hearing before a panel of the Board was held on April 13, 1999. This show cause hearing was limited to oral argument, some testimony by the Respondent's owner and pharmacist, Behrooz Goodarzi, and an examination of the inventory prepared by the Division of Drug Control inspector, C. Putz, based upon her observations of the Pharmacy on March 24, 1999 and March 30, 1999.

FINDINGS OF FACT BASED ON PROBABLE CAUSE

Based upon the investigation and the show cause hearing, the Board has reason to believe there exists probable cause that the following facts are true:

1. At all times relevant, the Respondent operated as a pharmacy in the State of Maryland.
2. At all times relevant, the Respondent operated as Melwood Pharmacy at 9644 Marlboro

Pike, Upper Marlboro, Maryland 20072 (the "Pharmacy").

3. At all times pertinent hereto, Behrooz Goodarzi, P.D. (The "Pharmacist"), a licensed pharmacist in the State of Maryland, has held the pharmacy permit for the pharmacy.

4. Acting on a complaint that expired drugs had been dispensed at the Pharmacy, the Division of Drug Control performed an inspection on March 24, 1999, at the Melwood Pharmacy. A follow-up inspection was performed on March 30, 1999.

5. Upon inspection, the following was found:

- a) Liquid medications were stored in soda bottles;
- b) There were numerous products without lot number or expiration dates.
- c) There were over 525 outdated products;
- d) The Pharmacist was not aware that he should destroy outdated CDS, and DEA form 41 was provided to him;
- e) There were expiration dates and lot numbers covered by the price stickers;
- f) Loose pills were found on the shelves;
- g) The outdated products date as far back as 1987.

6. The following is a list of outdated products by category¹, found at the Pharmacy on March 24 through 30, 1999: electrolyte supplements, anti-psychotics, anti-hypertensive, antibiotics, antitussives, antihistamines, acid blockers, circulation medications, Antibuse, pain relievers, Alzheimer management medications, tranquilizers, diuretics, prenatal vitamins, medications for the

¹ Attached as part of Exhibit #1 and incorporated by reference is the inventory of March 24, 1999, and March 30, 1999, prepared by C. Putz of the Division of Drug Control and signed by Respondent.

control of obsessive compulsive disorders. anti-inflammatory creams. steroidal. antigout products. acne lotion. saliva substitute. progesterone. antibiotic acne liquid. aspirin/codeine products. antivirals. calcium channel blockers. pain relievers. expectorants. enemas. anti-inflammatory medications. sleep aids. pediculacide. UTI medications. vitamins. urinary antiseptics. antinausea. anti-ulcer. mobility agents. anticoagulants. thyroid supplements. anti-depressants. muscle relaxants. tuberculosis drugs. antiarrhythmic heart medications. antidiabetics. asthma medications. oral contraceptives. ear anti-infectives. potassium supplements. anti-miasthenics. antiseizure products. bulk hormones for compounding. laxatives. Schedule III² cough suppressant/expectorants. Schedule III pain relievers. Schedule IV tranquilizers. and Doral, a Schedule IV sedative. In addition to the above. these categories of pediatric specific medications were found: expectorant/decongestants. numerous antibiotics. cough/cold preparations. asthma and pain relievers. A bottle of Diethylstilbesterol. with an expiration date of May. 1994 was also found on the shelf of the Pharmacy. Diethylstilbesterol is no longer on the market.

7. At the show cause hearing the Respondent defended his practice of putting liquid medications such as Zyrtec syrup into soda bottles despite the risk of contamination. His continued insistence in defense of this practice demonstrates incompetence and disregard for the public health and safety.

8. At the show cause hearing the Pharmacist claimed that he never had a chance to get rid of the outdated drugs and admitted that he had no system to flag outdated drugs. At the hearing he claimed that he has changed his practices since the inspection so that on each day he now pulls all

² Some of the products previously listed are scheduled drugs.

outdated drugs off the shelves. He further stated that he now keeps his containers upside down when they are drawing near to the expiration date.

9. At the show cause hearing the Pharmacist claimed there were only 362 bottles of outdated products rather than 525. He admitted that "maybe" some of these outdated products had been on the shelf. The Board finds that it is most likely that many of these bottles were on the shelves and contained outdated drugs as reported by the inspector. Furthermore, there is absolutely no legitimate reason to have these quantities of outdated products in the store. Outdated pharmaceutical products can cause substantial harm to patients and the Board finds that there was no valid reason to possess these products in such numerous quantities and for such long periods of time. To possess these numerous quantities of outdated pharmaceutical products either shows extreme incompetence or an intent to dispense these outdated products. In either event, emergency action is required to protect the public.³

10. Because the Pharmacy is being operated in an incompetent manner that exposes the public to the grave dangers of outdated drugs, the Board finds that emergency action is necessary to protect the public health, safety, and welfare.

CONCLUSIONS OF LAW

Based upon the foregoing Findings of Fact Based on Probable Cause, the Board finds that

³ The Board is especially troubled by the presence of such outdated pharmaceutical products as pediatric medications, antibiotics, anti-hypertensives, antiarrhythmic heart medications, anti-psychotics, antivirals, progesterone, oral contraceptives, thyroid supplements, tuberculosis drugs, and medications used to control obsessive-compulsive disorders.

the public health, safety and welfare imperatively requires emergency action pursuant to Md. Code Ann., State Gov't Art., § 10-226(c)(1) and Md. Code Ann., Health Occ. Art., § 12-409(a)(1) and (2).

ORDER

Based upon the foregoing Findings of Fact Based on Probable Cause, it is this ____ day of _____, 1999, by a majority of the quorum of the Board, hereby

ORDERED that the Respondent's pharmacy permit be summarily suspended pursuant to Md. Code Ann., State Gov't Art., §10-226(c). And be it further

ORDERED that this a **FINAL ORDER** and as such is a public document pursuant to § 10-611 *et seq.* of the State Government Article, Annotated Code of Maryland. And be it further

ORDERED that this Order for Summary Suspension of Pharmacy Permit and the same is hereby effective on the day that it is signed. And be it further

ORDERED that the Respondent shall submit the original display permit no. P01278 for Melwood Pharmacy to the Board's offices. And be it further

ORDERED that Respondent shall submit to a closing inspection of the pharmacy to be conducted pursuant to COMAR 10.34.14 and shall otherwise cooperate with the Board and the Division of Drug Control in carrying out the Respondent's obligations for the closing of pharmacies in accordance with COMAR 10.34.14. And be it further

ORDERED that provided that the Pharmacy is not open to the public, the Pharmacy may remain in operation for two weeks following the effective date of this Order for the sole purpose of returning and disposing of drugs held in the pharmacy and for transferring prescription information to other pharmacies. And be it further

ORDERED that the products detained by the Division of Drug Control shall be retained in the Pharmacy until requested by the Division of Drug Control.

4/21/99
Date

W. Irving Lottier, Jr.
W. Irving Lottier, Jr. P.D.
Secretary, Board of Pharmacy

IN THE MATTER OF
MELWOOD PHARMACY
PERMIT NO. P01278

* BEFORE THE
* MARYLAND STATE
* BOARD PHARMACY

RESPONDENT

* * * * *

**BOARD'S RULING ON RESPONSE
TO CHARGES AND MOTION TO DISMISS**

For the reasons set forth below, the Board denies the Respondent's Motion to Dismiss Summary Suspension Hearing.

Respondent argues that dismissal is required because the original unexecuted order erroneously cited Md. Code Ann., State Gov't Art., § 10-405(b) because it was a repealed law. At the show cause hearing the Administrative Prosecutor acknowledged that this was typographical error and provided the Board with a new unexecuted summary suspension order containing the accurate citation for the summary suspension statute, i.e., Md. Code Ann., State Gov't Art., § 10-226(c).

The Respondent was on notice of the factual allegations that caused the Board ask him to show cause why the Pharmacy Permit should not be summarily suspended. The text of the former §10-405 is identical to that of the present §10-226(c). It is an obvious typographical error given that the correct citation was contained in the companion unexecuted summary suspension order regarding Behrooz Goodarzi's pharmacist's license, that was also delivered to the Respondent's sole permit holder, Mr. Goodarzi.

A mere renumbering of an identical statute is an insufficient basis upon which to dismiss an action given that Respondent was on notice regarding the factual allegations that would support a

summary suspension. Notice given to Respondent at the show cause hearing that there was a typographical error and the submission to his attorney of an amended unexecuted summary suspension order at that hearing containing the accurate statutory citation was sufficient notice to comport with principles of due process.

It is also obvious that the Respondent was in fact aware of the reenactment of §10-405 as §10-226(c) because he writes that §10-405 “was repealed in 1993 and was not reenacted *under that section number.*” (Emphasis Added). It is quite clear that the Respondent was aware of the continued existence of §10-405 as §10-226(c) but chose to make a hypertechnical argument rather than to address the serious safety concerns raised by the factual allegations contained in the unexecuted summary suspension order. Because the typographical error was corrected at the hearing, the Respondent was given sufficient notice of the applicable law prior to the Board taking action. The Respondent’s legal defense was not prejudiced by this typographical error.

“As has often been stated, ‘[d]ue process does not require adherence to any particular procedure. On the contrary, due process is flexible and calls for such procedural protections as the particular situation demands.’ ” *Maryland Racing Commission v. Castrenze*, 335 Md. 284, 299 (1994) (citations omitted here). The *Castrenze* upheld the summary suspension of a license prior to giving the licensee an opportunity to be heard. An important factor for The *Castrenze* court was the scope of the issues to be resolved at the hearing. *Id.*, 335 Md. at 300. The scope of the issues here was limited to whether the observations recorded in the Division of Drug Control Inspection Report constituted probable cause that the public health, safety, and welfare imperatively required emergency action. That issue was clearly stated in the original written notice to the Respondent and was not changed in any way by providing him with the accurate statute number at

the hearing. Thus, he clearly had an opportunity to prepare a defense and therefore was not prejudiced by this typographical error.

The process given in this case was clearly appropriate given the potential threat to the public health and the consequent need for quick action by the Board to protect the public health. "As has often been stated, '[d]ue process does not require adherence to any particular procedure. On the contrary, due process is flexible and calls for such procedural protections as the particular situation demands.'" *Maryland Racing Commission v. Castrenze*, 335 Md. 284, 299 (1994) (citations omitted here). The *Castrenze* Court upheld summary suspension of a license prior to giving the licensee an opportunity to be heard. An important factor for the *Castrenze* court was the scope of the issues to be resolved at the hearing. *Id.*, 335 Md. at 300. The scope of the issues here was limited to whether the observations recorded in the Division of Drug Control inspection report constituted probable cause that the public health, safety, and welfare imperatively required emergency action. That issue was clearly stated in the original written notice to the Respondent. Thus, he was notified as to the relevant factual and legal issues so that he could prepare a defense.

The *Castrenze* court also held that another important factor to consider is the balancing of the government's interest against the licensee's interest. *Id.*, 335 Md. At 300. In this case, the Board's interest in avoiding irreparable injury to the health and welfare of Maryland's citizens clearly outweighs the Respondent's more limited property interest in avoiding the erroneous deprivation of his pharmacy permit. *See Varandani v. Bowen*, 824 F.2d. 307, 310 (4th Cir. 1987), ("the courts have refused to require anything more than an informal hearing before a doctor is suspended from Medicare reimbursement in large part because of the interest of Medicare patients in not being treated by a doctor found by his peers to have engaged in substandard practice."). *See*


also, *Waltz v. Herlily*, 682 F. Supp. 501 (state may summarily suspend physician's license provided that adequate post-deprivation remedies are available); *Morton v. Beyer*, 822 F.2d. 364, 369, n. 11 (public employee who poses a significant hazard is not constitutionally entitled to any kind of hearing). Thus, under these cases, the Respondent was given more process than is due under principles of constitutional law.

In addition, the Respondent was given more process than is required under Md. Code Ann., State Gov't Art. §10-226(c). Under that section, the Board could have suspended the license and then provided him with the reasons for the suspension afterwards. Instead, the Board chose to give the Respondent a pre-deprivation hearing and provided him with advance notice prior to taking action against his license. Provision to the Respondent of the amended unexecuted summary suspension order at the hearing containing the sole change of the renumbered statute provided him with more notice than was even required under §10-226(c).

For all the foregoing reasons, the Respondent's motion to dismiss is denied.

4/21/99
Date

W. Irving Lottier, Jr.
W. Irving Lottier, Jr., P.D.
Secretary, Board of Pharmacy



IN THE MATTER OF
MELWOOD PHARMACY
PERMIT NO. P01278,
RESPONDENT

* BEFORE THE
* MARYLAND STATE
* BOARD OF PHARMACY

* * * * *

ORDER FOR SUMMARY SUSPENSION OF PHARMACY PERMIT

Based upon the information received by the State Board of Pharmacy (the "Board") regarding Melwood Pharmacy (the "Respondent"), under PERMIT No. P01278 for Melwood Pharmacy located at 9644 Marlboro Pike, Upper Marlboro, Md. 20072 the Board has reason to believe that the following facts are true:

BACKGROUND

1. Respondent is a pharmacy which has been issued a permit to be established and operated as a pharmacy in the State of Maryland.
2. At all times relevant, Respondent operated as Melwood Pharmacy at 9644 Marlboro Pike, Upper Marlboro, Md. 20072 (the "Pharmacy").
3. At all times pertinent hereto, Beehrooz Goodarzi, P.D. (the "Pharmacist"), a licensed pharmacist in the State of Maryland is the holder of the pharmacy permit for the Pharmacy.
4. The Division of Drug Control performed an inspection on March 24, 1999, at the Melwood Pharmacy located . A follow-up inspection was performed on March 30, 1999.
5. Upon inspection the following was found:
 - a) Pharmacist did not have the required CDS biennial inventory available;
 - b) the generic manufacturer was not recorded on the prescriptions;
 - c) the Schedule II drugs were found in a plastic bag on the floor of the pharmacy;

current Department of Health and Mental Hygiene Permit No. P01278; and be it further

ORDERED, ORDERED, that a show cause hearing shall be scheduled on **Tuesday, April 13, 1999, at 1:30 p.m.**, at 4201 Patterson Avenue, Baltimore, Maryland 21215 at which the Respondent will be given an opportunity to be heard on the issues limited to those raised in this Order. Any such hearing will be held before the Board or its designee; and be it further

ORDERED, that a copy of this Order shall be filed with the Board; and be it further

ORDERED, that this is a public document and as such is considered a public record pursuant to Md. Code Ann, State Gov't § 10-611 et seq. (1995 Repl. Vol.)

NOTICE OF HEARING

An evidentiary hearing will be scheduled before the Board at 4201 Patterson Avenue, Baltimore, Maryland 21215 upon Respondent's written request. Any such hearing will be scheduled to be heard by the Board within thirty (30) days of receipt of Respondent's written request therefor.

Date

W. Irving Lottier, Jr., P.D.
Secretary, Board of Pharmacy

EXHIBIT A

STATE OF MARYLAND
DEPARTMENT OF HEALTH AND MENTAL HYGIENE
INSPECTION REPORT
Division of Drug Control

SHEET 2 OF 3

DATE 3-30-99

Malverton

Pharmacy Name
ITEM No.

LIST OF OBSERVATIONS

Cardiazem 180mg repackaged with label with no lot # or exp date
Label cut from physician sample, X amoxic 2mg 1/95
Android 25mg IGN 7/96

Procardia XL 60mg GITS lot # 15598 exp 12/1/95 physician
Repacked by CVS Malverton RI 02895 item 671875
NDC 0069-260-66

Danosone 200mg 2/95, Imipramine 25mg 7/98
Dexamethasone 2mg ^{tablets} unit dose package with ~~lot #~~ 1884 Aug 1 1996
C556XN 09
Malverton

Danosone 71 10/97, Rx 045628 for Dexamethasone on shelf
exp 4/13/91

Danosone Sprinkle 4/94 (Adams Lab)

Lasin 80mg ^{tablets} 3/89, Clonidine Patch samples 7/89
4/90

Costomasa 9/98, Hydroxyzine 10mg Zenith 12/87,

Cotazym 11/97, Cardiazem SR 60mg 9/97

Unlabeled Rx vial - blue & yellow capsules

Goendin 50mg 3/92, Doxosuprim Tablets Ruffy 10mg


Diabeta 5mg 10/98, Verelan 240mg 11/97

Regulin 200mg 2/99, Oura-Vent /DA 1/99

Cardiazem 90mg 6/94 (green tablet)

Zestril 10mg - repackaged National Pharm Pak Service Inc
Lot # CRH 700 Zanesville, Ohio 43701
L 23254198
240 05/00

Received by _____ Inspected by _____



STATE OF MARYLAND
DEPARTMENT OF HEALTH AND MENTAL HYGIENE
INSPECTION REPORT
Division of Drug Control

SHEET 3 OF 8

DATE 3-24-98

Wellwood

Pharmacy Name
ITEM No.

LIST OF OBSERVATIONS

Outlets:
 Methyldopa and Hydrochlorothiazide Tablets 50mg/30mg (Jalov) 5/1988,
 Aldomet 25 9/87, Bromfed 6/97, Epresomite 50/50 2/94,
 Bromfed-PT (empty bottle) 9/97, Altace 10mg 2/98,
 Aldomet 25, 1/98, Ovid Jan 1, 1994, Adalat CC 30mg - label
 pasted on bottle no lot # or exp. date, Altace 2/98,
 Methyldopa 50mg Disulfiram 2/95, Oriscept 5m - bottle with
 label cut out and pasted on bottle no exp date or lot #,
 Apronidone and HCTZ 25/25mg 3/94, Spinolentan and HCTZ 25/25mg
 (URL) URL 11/
 Hydralazine H-1 - HCTZ 25/25 (color) Jan 1992
 Aldomet 125g 4/89, Altace 205mg 1/98, Anaproxol 25, 1/96,
 Benemid 0.5g (empty bottle) 5/89, Anapro 150g relabeled with
 cut off label pasted on, no lot # or exp date, Benemid 2g empty b
 10/19
 Benmetamide 0.5g 10/1/86, Benemid 0.5g 6/1/96, Benmetamide 0.
 Clinacil 150g 1/94, Combist LA 2/88, Cycasin - no exp date -
 Lot #, bottle label cut off and pasted on, Col Benemid 12/97,
 Erginon with Codeine #4 12/95, Plendil 5mg 4/97, Plendil 6/9
 Doral 10/96, Doral 9/96, Plendil 2.5g label pasted on bottle
 no lot # or exp date, Plendil - report exp with pasted label in R, or
 Mucotens Exp. 11/94, Latid Elixir reported with pasted label no lot #,
 Mucotens Exp 11/94 empty bottle, in another lot #,
 Nalidixate Peak Signa 12/97, Prednisone Syrup empty bottle in d
 Luria Substrate (Revere) 3/94, Sulfonyl Urea Tablet 7/90
 Dermotop 2/96, Holotens Cream 1.0% 1/94, Cyclocort or 12/
 Clin Longey Sol. 1% 11/97,

Received by [Signature]

Inspected by Catherine J. Long

STATE OF MARYLAND
DEPARTMENT OF HEALTH AND MENTAL HYGIENE
INSPECTION REPORT
Division of Drug Control

DATE 3-24-98

Mellwood

Pharmacy Name
ITEM No.

LIST OF OBSERVATIONS

	Zorprin 500g (Aspirin) repack with labels pasted onto another one
	no exp date on lot #, Zorprin 1/94, Suproic 10/97
	Vartan ^{500/500} 12/96, Vartan ^{100mg/500} 2/98, Cephradine 250g ^{6/1/95}
	Zovirax 800g 9/96, Zylegrin 300g 3/97, Fulvicin PG 330 ^{6/98}
	Zenith ^{Primatec U.S.} 6/95, Floxin 300g (empty bottle) 5/98, Zylorin 300g ^{3/98}
	Keflex 250g 6/1/95, Ziac 2.5g 8/98, Lorabid 200g 15ml 4/1/98
	Flazyl 500g 1/97, Zorprin ^{Both 100 ASA 300g 3/91}
	Diclofenac ^{oral susp} 9/98, Syngene oral susp 12/97, Ziac 5g 12/98
	Trandate 100g 3/93, Hydroxyzine Pamote no exp. date on lot #
	Hydroxyzine Pamote 25g (zenith) 12/95, Dicizipin 2g (zenith) 10/9
	Urinary Antiseptic Tablets (Alph. cyn) Mason's order # 21440 9/27/94
	exp Nov 95, Vicin forte 3/99, Trandate 300g, Uripas Jan 31, 199
	Zenith Chlorzoxipate 7.5g (Top Rx 3/16/98 613422) same as Transver
	5/98, Chlorzoxipate 3.75g 9/95, Choline Mg 500g 5/96
	Flazyl 375mg 1/99 (unit dose x 8 capsules)
	Lorabid 200g Jan 1, 1999, Augmentin for Oral Susp 125g 15ml 12/
	Benzocaine 250g (Wainor Chilcutt) 7/98, Lorabid 200g Jan 1, 1999,
	Sulfamethoxazole and Trimethoprim 400/80 (Schein) 2/97
	Cefzil - tablet repackaged in Ruvic - no lot # or exp date
	Clonidine 1.50g capsules 4/95, Dynabac 250g Sept 1, 1997
	Lorabid 400g Aug 1, 1998, Augmentin 125g ^{chewable} unit dose tablet 1/92
	Augmentin 250g ^{chewable} unit dose packaged tablet 8/98
	Augmentin 200g ^{chewable} u.d., Floxin UroPak Samples (6 tabs)
	no exp date - date of packaging 8-1-95, Cefaclor 500g repackaged
	Re vid - no lot # or exp. date

Received by J. Gray Inspected by Catherine J. Gray

STATE OF MARYLAND
DEPARTMENT OF HEALTH AND MENTAL HYGIENE
INSPECTION REPORT
Division of Drug Control

DATE 3-24-99

Mallwood

Pharmacy Name
ITEM No.

LIST OF OBSERVATIONS

Stetogen 1mg exp 3/95 (no lot # repackaged), ^{General} ~~Ammon~~ ^{11/96}
 Sodium Chloride 1gram 7/1/1988, Triphenylethylamine 2mg ^{11/96}
 Synthroid 200mg repackaged with partial on label in Rx vial with
 no lot # or exp date, Cordex TR (Baldwin) labeled with
 Ronda TR tab on it also 3/99, Tuss-tan 4/97 labeled with
 Repetax written on regular label, ^{Major} ~~Dorepin~~ ^{11/96}, ~~Some Cpl~~ ^{1/87}
 Refadin 300g 9/98, ~~Sectral~~ 400g exp date + lot covered -
^{General} Triphenylethylamine 5mg 6/98, Regulin 200mg 9/98,
~~Allo-bid~~ 100mg 4/97, ~~Methocarbamol~~ oral ASA 400g/325g ^{Zenith} 8/95
~~Allo-bid~~ 100mg 12/96, ~~Sempres-D~~ capsules - label gated on - ^{Major} ~~no lot #~~
~~Reparin, hydrolysis~~ ~~HTZ~~ 0.1g/25/15g (Dunbury) 3/94, ~~Tri-Tan~~ 5/9
^{Major} Triphenylethylamine 10g 6/93, ~~Bronchyl~~ gel 9/95, ~~Propranolol~~
~~Keralog~~ 0.1% cream 8/95, ~~Propranolol~~ cream
~~Paral-Gel~~ 10% 12/92, ~~Meclera~~ Cream No. 11/94,
~~Meprobamate~~ ~~Zytrec~~ ^{liquid} ~~repacked~~ in other bottle with label pasted on
~~Ortho-Novon~~ 1/50 28 day 12/94, ~~Prodi-Cin~~ 28 4/97
~~Demulen~~ 1/50-28 3/96, ~~Ortho Cyclon~~ - samples, ~~Loestrin~~ 2
~~Oral-28~~, 1/97, ~~Pilopine~~ HS Gel 9/97,
^{Sungarin} ~~Cardiazin~~ ~~Oral~~ 10/98, ~~Coly-Mycin~~ 5 tabs 9/97, ~~Rem-k~~ ^{Sangaris} 6/98
~~Tussal - Organidin~~ DM 2/87 (empty bottle), ~~Demetone~~ DC conf 7/1
^{Bone} ~~Dopen~~ ~~Elin~~ 8/96, ~~Amberlyl~~ ~~Comp~~ ~~Syrup~~ 1/88, ~~Alsept~~ ~~Syrup~~
~~Bronch~~ DM ~~Comp~~ ~~Syrup~~ - labeled with handwritten serially label ~~Demetone~~ - D
 (empty bottle) 6/94, ^{Bone} ~~Bronch~~ ~~Comp~~ ~~Syrup~~ 7/98, ~~Ronda~~ ~~Syrup~~ 2/1
~~Pedipart~~ 1/95, ~~Uroson~~ SF (labeled with ~~Robit~~ ~~DAC~~ also on it) 8/9
^{Bone} ~~Dופן~~ 6/96, ~~Tussor~~ - 2 (vial - bottle) 9/93, ~~Triacin-C~~ ~~Comp~~ ^{12/96} ~~outfit~~

Received by [Signature] Inspected by Cath S. [Signature]
Dופן C Liquid 2/97, Dופן - C liquid 2/97

STATE OF MARYLAND
DEPARTMENT OF HEALTH AND MENTAL HYGIENE
INSPECTION REPORT
Division of Drug Control

DATE 3-24-99

Mellum

Pharmacy Name
ITEM No.

LIST OF OBSERVATIONS

bottle of unlabeled capsules in box with Indinavir LA 80/50g
 Propipendol + HCTZ 80g/25 (Melfon) 2/92
 Propipendol + HCTZ 80/25g 2/92 (another bottle)
 Indinavir LA 160mg 3/92, Indinavir LA 60g 7/97
 Indinavir 80mg (Capsule) 11/98, Indinavir LA 60mg 8/96
 Mellaril 10mg 7/94, Lorazepam (ER) 40mg 11/94
 Zopimor 160mg 4/98, Motrin (one with vit) 11/97
 Motrin 10/1/97, Lorazepam 30g 3/94, Mefenamic acid 50g 2/92
 Mellaril 15mg tablet July 89, Mefenamic acid 50g 7/97
 Lotrel 2.5/10 10/98, Thiothixene cap 5mg 10/98, Propipendol 10/9
 Thiothixene 10g 1/98, Melfon 600g 2/1/93
 Quinidex 300mg capsules 3/94 cap, Pyridium Plus 11/89
 Amisulpride (SA) same as Mellum Jan 96(?)
 Erythromycin Susp. 400mg/5ml 9/98, Erythromycin 5mg 10/98
 Minipress 27 May 95, Amisulpride 5-50 5/50g 3/98
 Midamor 5mg 6/92, Modurite 5-50 6/96, Plavix 200mg 5/9
 Pruridon 350g 9/95, Minocyclid 10g 5/90
 Minocyclid 2.5mg 8/95, Polaramin 8/95, Poly-biotin D 2/98
 Thiothixene 2mg 2/98, Prandin 0.5mg Sample bottle should
 only have 12 tablets - has over 100 tablets in cap. 1/2000
 Probu-2 10.5mg 7/95, Provera 100g 8/97, Provera 12/98 2.5g 5mg
 Disopyridamide tablet 75g 9/97, Proventil 4g 12/95
 Prochlorperazine Susp 25g 12/97, Provera 5mg 9/98 Provera 50g 1/9
 Provera 5g 2/99, Provedol 10g 6/97, Polaramin 6mg 10/9
 Provera 2.5g 3/97

Received by [Signature]

Inspected by [Signature]

STATE OF MARYLAND
DEPARTMENT OF HEALTH AND MENTAL HYGIENE
INSPECTION REPORT
Division of Drug Control

SHEET 7 OF 8

DATE 3-24-99

Pharmacy Name
ITEM No.

Mellinwood

LIST OF OBSERVATIONS

DO NOT
SIGN

original

Temazepam 15mg 11-98, Synthroid 150
 Bupropion tablets 1mg 1/99, Compazine 2
 Isoniazid 400mg 6/96, Col-Probenecid (URL) 10/98
 Bupropion 0.5mg Scher 11/97, Codeine LA 10/96
 Bupropion 0.5mg Scher 10/98, Codeine LA 10/96
 no exp. date on lot #, Compazine 5mg 8/11/97, Dic Betas 2.5mg 7/97
 Dyanine Capsules 1/31/95, Bottle of approx 1000 tablets reported
 with posted on BuSpan 15mg label lot # MK094E, exp 1 Nov 99
 (Pharmacist explained he repackaged a lot of small bottles he had
 purchased from a store) Buspar 5mg 2/99
 Prenate Ultra samples exp 11/98, Proctex 6/95
 Glucotrol 10mg 8/98, ~~Compazine 5mg~~ Trichloroethylene 1cc 2mg 3/95
 Calan SR 180 SR 10/98, Triamcinolone 4mg Jan 90,
 Amoxicillin 100mg June 97, Calan 80mg 9-88, Verapamil 10/98
 Ornade. Tablets expire 1997, Orange rd multicolored capsules
 with Ornade written on it, Bestojidien 100mg 3/93
 Phenylephrine 100mg 4/92 (orange tablet), PB2-SR 100mg 11/95
 Tolbutamide 500mg 1/98, Dural 300mg Anesthet - Inim, Co
 Dextrose Glycerol 30mg NDC # 55053-250-05
 Ted. Conton 5/96, (x 2 bottles), Librium 5mg - repackaged with posted on
 label with 11-1-96 exp date (yellow-green round)
 Chloridiazepoxide 10mg 8/98, Lersinex Timcaps 12/97
 Lorazepam 100mg 10/94, Chloridiazepoxide 25mg 9/97
 Lorazepam 150mg 11/94, Chloridiazepoxide + Amitriptyline 10/25 7/95
 Lorazepam 10/650, 10/98, Loro (Anbid) 20mg 9/98

Received by

[Signature]

Inspected by

[Signature]

STATE OF MARYLAND
DEPARTMENT OF HEALTH AND MENTAL HYGIENE
INSPECTION REPORT
Division of Drug Control

SHEET 3 OF 3

DATE 3-30-99

Mohammed

Pharmacy Name
ITEM No.

LIST OF OBSERVATIONS

Noromodyne 200mg pink color repack by
Drug Distribution, Inc. Buffalo NY 41714
0085-0752-04 exp March 2000
Lot 7RHR 778

Schering 6505-01-209-1212

Cyproheptadine Tablets 4mg (Schering) 9-96, Demerol 200mg ^{11/94}

Diprivan 25mg 12/90 (Schering) white coated tab #25

Diethylstilbestrol tabs (Lilly) 5mg 1/1, 1994

Darvon-N 100mg 8/1/93, D.A. Chewable Tablets 9/94

Cotazone 0.3mg Jan 94, Propoxyphene Cpd 65 (Schering) 2/97

Phenergan 12.5mg 4/96 orange tablet #19, Cyproheptadine 4mg ^{12/97}

Hytrin 5mg Dec 1, 1998, Hytrin 10mg Feb 1, 1999, Poly-histone 2/9 ^{3/6}

Calan ^{SR} 240mg, repackaged with label with exp. 3/97, Max Green 500mg

Milrin Losp 6/97, Bicxin 500mg March 1, 1995

Amaryl tablet 2mg 1/99, Carafate 16mg March 98

Trental 400mg 2/99, Amaryl 1/99, Tem-k 10mg 11/91

Multivert - Tab 500mg 4/95 (Copley Pharm. Inc.)

Levorotemide Tablet USP 40mg unit dose of distribution ^{Mar 92}

210-7555

UDL ex 3/00

D855A

Lot 8C 551

13 2
Mellin's Hx1

N 5107907301

Received by _____ Inspected by _____